I
nflammatory bowel diseases (IBDs), Crohn's disease and ulcerative colitis, are chronic inflammatory disorders affecting mainly the gastrointestinal tract. IBD is a complex disease: genetic, immunologic, and environmental factors have all been implicated in the development of the intestinal inflammation and dysregulation characterizing it. 123 IBD genetics has been widely studied through genomewide association studies (GWAS) and differential gene expression analysis. [4] [5] [6] So far, hundreds of genes are implicated in IBD etiology. Although it is expected that more genes are involved in its pathophysiology, 7 current approaches are limited by the extremely high number of samples required to identify significant associations and by the challenging task of analyzing highly variable expression data. Despite the tremendous efforts put into gene discovery, the full diversity of IBD-risk genes remains unclear. 8, 9 In this study, we developed a machine learning-based method for the purpose of prioritizing IBDrisk genes to detect candidate novel IBD-associated genes.
MATERIALS AND METHODS

Overview
Our method was trained to classify genes as either conferring or not conferring risk to IBD using both numerical expression data (microarray and RNA-seq) and categorical terms retrieved from the gene ontology (GO), 10 Kyoto encyclopedia of genes and genomes (KEGG) pathways, 11 and the Pathway Interactions Database. 12 The method was generated using supervised learning with instances including genes with known IBD association serving as the positive samples, and genes that have no association to IBD serving as the negative ones.
(35.1%), 149 ulcerative colitis (29%), 94 colorectal neoplasms (18.3%), and 90 normal tissue (17.5%). Negative and positive gene instances are required to train the different IBD-risk gene prioritization models. Positive gene instances (corresponding to known IBDassociated genes) were collected from published associations found through GWAS based on extensive cohorts. 6, 9 To compile the list of negative gene instances (corresponding to genes that are unrelated to IBD), we selected genes associated with diseases unrelated to the disease being studied. This method has been previously used in prioritization studies to reduce the likelihood of selecting a gene associated with the disease in question. [20] [21] [22] Negative gene instances were collected in the following way: (1) A list of all known gene-disease associations was downloaded from the ClinVar database. 23 (2) To avoid instances in which a gene is considered unrelated although it is associated with a disease that shares genetic components with IBD, diseases with associated genes that included the positive gene instances were removed from the list. (3) Two thousand genes were randomly sampled from the remaining list. Some of the genes were removed from the analysis because of high rate of missing values in the various features. The final gene list included 314 IBD-associated genes and 1736 non-IBD genes. KEGG pathways 11 and the Pathway interaction database 12 data were downloaded from the Molecular Signature Database (MSigDB). 24 GO ontology 10 data, including cellular component, molecular functional, and biological process were collected from the feature data included in the GEO data sets. To limit the number of included features, we included only GO terms that were present in at least 1% of the genes. Terms from all 3 data sets were converted into binary features with a value of 1 if the term is included in the gene annotations and 0 if it is not. The final data set was composed of 2050 genes. Each gene was annotated with 1027 different features: 514 binary values corresponding to the ontology and pathway terms and 513 numeric values corresponding to its abundance in each of the expression data samples. (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B612).
Preprocessing and Training Scheme
The original data set was divided into 2 sets, one for training the model (75%) and the other for validation (25%). Numerical features were scaled and centered at 0. Model training and performance assessment were performed using a 5-fold crossvalidation that was repeated 10 times. Briefly, cross-validation is a strategy used to asses how a given prediction model will generalize to other independent data sets. This strategy is often used during prediction model training to reduce the probability of generating a model that performs well only on the data set used to train it (e.g., over-fitting). In cross-validation, the training set is partitioned into 5 complementary subsets, the model is trained using 4 subsets and evaluated on the remaining 1. This is performed on each of the 5 subsets, and the performance metrics are averaged across subsets. In repeated cross-validation, the aforementioned steps are repeated 10 times, each time with a different partition of subsets and the performance metrics are averaged across repeats as well. To prevent over-fitting, repeated cross-validation was used during both the feature selection step and in the following training step.
Feature Selection and Classification Models
To reduce the dimensionality of the data set and identify the features that characterize IBD genes the best, we implemented an elastic net regularized generalized linear model using the R package glmnet. 25 This method selects features by identifying features that do not contribute information to the model and reducing their coefficients to zero. Features that had non-zero coefficients when ran on the training set were selected and incorporated into subsequent model training. Feature importance was calculated and scaled between 0 and 100 using the "caret" R package. 26 To prevent over-fitting, feature selection was performed using only the training set. The size of the coefficients was retrieved from the final glmnet model. Using the selected features, we trained 4 different machine-learning classification models as follows: Random forest (rf), 27 support vector machine with polynomial kernel (svmPoly), Extreme gradient boosting (xgbTree), and elastic net regularized generalized linear model (glmnet). 25 Each model produced a score between 0 and 1, corresponding to the level of confidence in which a gene is considered an IBD-risk gene. In addition to evaluating the performance of each model separately, we calculated the average of the scores output by the models and evaluated the performance of the combined score.
Parameter Optimization and Performance Evaluation
Each classification model was ran with a variety of parameter combinations to identify the best performing setting. In addition to the area under the curve (AUC), models were evaluated using the following metrics:
ðiiÞ Sensitivity:
ðiiiÞ Specificity:
Performance was evaluated on both the training data set (the left out subset in each cross-validation round) and a test set (25% of the original data set), which was not used in any step of the training process.
Score Rank Test
To assess how our models perform on the entire gene data set, we randomly sampled 400 genes from the full list of genes, omitting genes that were included in the training process. We then added 1 known IBD gene from the test set (an IBD gene that was not included in the training process) to the gene list. Although the composed list may contain additional IBD genes, we expect the added IBD gene's score to be ranked within the top percentiles. We performed the sampling process 2000 times, each time with a random sample of genes and a randomly selected IBD gene. We then summarized the score percentile for the IBD gene in each sample.
Enrichment Test
Gene set enrichment analysis was performed for both the list of known IBD genes and for a list composed of all the high-scoring genes (.0.8) that were not included in the training process. Enrichment analysis was performed on GO terms and pathways using the ToppGene web server. 28 The 2 lists of significantly enriched terms (P , 0.05) were compared, and a final list composed only of terms enriched in the high-scoring genes and not in the list of known IBD genes was generated. To remove as many terms, the known IBD terms were filtered with the Benjamini-Hochberg correction for multiple hypothesis testing, and the list for the high-scoring genes was filtered using the more strict Bonferroni correction.
Literature Search
An automated literature search was performed to assess whether a given gene has a known publication concerning IBD. Briefly, for each gene in the full 16,390 list, a PubMed query was run in this format: ",gene name. AND inflammatory bowel disease [mesh]" using the R package rentrez. The resulting PubMed identifiers were collected and counted. Logistic regression was used to test the association between the combined models score and the probability of having an IBD publication with the scores discretized into 10 bins of equal score ranges. The Wald test was used to test for the effect of each score bin and the overall effect of the score. To generate the final list of topscoring genes without an IBD publication, a manual review of the literature for each gene including its known synonyms was conducted to identify genes with an IBD publication missed by our automated search.
Statistical Analysis
One-sided Mann-Whitney U test was used to test whether the scores given by the models for the known IBD genes are significantly higher than the ones given to the non-IBD genes. Fisher's exact test was used to test for dependence between direction of association and healthy status in the expression data set.
RESULTS
Setup and Feature Selection
To train the method to classify genes as either conferring or not conferring risk to IBD, we first generated a list composed of FIGURE 1. Feature coefficients: Feature selection was performed using a regularized form of logistic regression, which reduces the coefficients of features that do not contribute to the overall model to zero. A positive coefficient represents a feature that characterizes an IBD-risk gene, whereas a negative coefficient represents a feature that characterizes a non-IBD risk gene. Reviewing the top features with the highest absolute coefficient values identifies terms associated with immunity and inflammation as likely to characterize IBD genes, whereas terms associated with oxidation reduction and coagulation are less likely to characterize an IBD gene.
314 genes identified to be associated with IBD through GWAS 6, 9 and 1736 genes that are not related to IBD. All genes were annotated with 1027 features including expression data from both array and RNA-seq data sets, GO, KEGG and the Pathway Interactions Database terms. To maintain interpretability and prevent overfitting, we searched for the most informative features for the task of differentiating IBD-risk genes from non-IBD risk genes (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/ IBD/B612). For this purpose, we implemented an elastic net regularized generalized linear model (glmnet). 25 Using this model, Models were trained on 75% of the known IBD genes and tested on the remaining 25%. Sensitivity, specificity, and accuracy values correspond to a threshold score value of 0.5.
FIGURE 2. Classification models evaluation: A ROC curve was generated for each of the models according to their performance on 75% of the original data set (A). An average score of all 4 models was calculated and was added to the evaluation as well. The calculated AUC ranged from 0.758 to 0.864. The scores for the known IBD genes (Y) were compared with the scores calculated for the non-IBD genes (N) and were shown to be significantly different across methods. To see how the different models generalize to genes that were not part of the original training set, we evaluated their performance on the remaining 25% of the data (B) demonstrating consistently high AUCs (0.775-0.829) and a significant difference in scores between IBD and non-IBD genes.
a coefficient was generated for each feature. A feature with a positive coefficient in the final model represents a feature that characterizes IBD-risk genes, whereas features with negative coefficients are not likely to characterize an IBD-risk gene (Fig.  1 ). Features with a coefficient equal to zero were deemed uninformative and were not included in subsequent steps. Reviewing the features selected by the method (N ¼ 309), we were able to explore what features define an IBD-risk gene.
Model Development and Validation
With the selected features, we trained 4 different machinelearning algorithms (Random forest [rf], 27 25 ) and further evaluated their performance on 75% of the known IBD genes (training set; Table 1 ). To improve performance estimation, models were trained and evaluated using a 5-fold cross-validation that was repeated 10 times. Comparing the scores predicted by the machine-learning models for the known IBD and the non-IBD genes demonstrated a significantly higher score for the IBD genes across all models (1-sided MannWhitney U test; P , 10 220 ) (Fig. 2) . In addition to evaluating the performance of each model separately, we calculated the average of the scores output by the models. This combined score demonstrated area under the ROC curve (AUC), sensitivity, specificity, and accuracy values of 0.852, 0.634, 0.914, and 0.847, respectively. To evaluate how the method can be generalized to genes not found in the training set, we tested its performance on the remaining 25% of the known IBD genes (test set; Table 1 ). The scores of the known IBD genes remained significantly higher across all models (P , 10 212 ; Fig. 2 ). The combined model demonstrated AUC, sensitivity, specificity, and accuracy values of 0.829, 0.577, 0.88, and 0.808, respectively.
The method was used to classify a list of 16,390 genes. Each gene received a score that was used to prioritize it according to its predicted association to IBD (see Table 2 , Supplemental Digital Content 2, http://links.lww.com/IBD/B613). To assess the method's performance on the entire data set, we performed a score rank test. 22 Reviewing the score rank of an IBD gene randomly selected from the test set in 2000 random gene samples, we demonstrated a consistently high ranking of the known IBD genes across models and samples (Fig. 3) .
Enrichment Analysis
An enrichment analysis was performed for the entire set of GO terms and pathways. Terms enriched in the list of known IBD genes were compared with those enriched in a list of high-scoring genes (.0.8) that were not used during model training. Of 880 enriched terms in the high-scoring genes list, 103 (11.7%) were not found in the known IBD genes enriched terms (see Table 3 , Supplemental Digital Content 3, http://links.lww.com/IBD/B614). Enriched annotations included terms associated with TRAIL binding, chemokine receptor binding, endopeptidase activity regulation, neutrophil activation, interleukin-5 production, pyroptosis, antigen presentation and processing, leukocyte adhesion, rolling, exocytosis, and chemotaxis. These terms represent characteristics of IBD genes that could not be asserted using only the list of known IBD genes.
External Validation: Literature and Public Databases
Although the method was based on known IBD genes detected by GWAS, there are many additional genes that have been associated with IBD through other methods. Implementing an automated literature search, we collected for each gene, in the full 16,390 list, all the articles ever published that concern IBD (see Table 2 , Supplemental Digital Content 2, http://links.lww. com/IBD/B613). Regression analysis revealed that there was a significant association between the predicted score and having an IBD publication across all models (Wald test; P , 10 220 ). In the combined model, having a score .0.9 (corresponding to the top 1% percentile) was associated with a high probability (0.78 6 0.12) for having at least 1 IBD publication (P , 2 · 10 216 ) (Fig.  4) . To further support the association between high-scoring genes and IBD, we compared the scored gene list against a comprehensive list of IBD-associated genes composed by DisGenNet. 29 Briefly, DisGenNet is a database and web server that integrates information on gene-disease associations from several public data FIGURE 3. Score rank validation: To assess how the different models perform on the entire data set, we performed a score rank test in which 2000 samples of a known IBD gene together with 400 randomly selected genes were generated. For each sample, the percentile rank of the known IBD-risk gene of the entire distribution of scores in the sample was calculated and counted. Known IBD-risk genes scores were ranked in the top percentiles (top 5%) in most samples.
sources and the literature. Regression analysis demonstrated a significant association between the combined predicted score and being marked as an IBD-associated gene in the database (Wald test; P , [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . In the combined model, nearly half of the genes with a score .0.9 were found to be IBD-associated by DisGenNet, with a calculated probability significantly higher than lowscoring (,0.5) genes (0.46 6 0.15 versus 0.06 6 0.004; P , 2 · 10 216 ).
DISCUSSION
The IBDs are chronic inflammatory disorders, associated with genetic, immunologic, and environmental factors. Although hundreds of genes are implicated in IBD etiology, it is likely that additional genes play a role in the disease process. We developed a machine learning-based gene prioritization method to identify novel IBD-risk genes.
To generate the initial list of IBD-associated genes, we gathered genes identified in 2 GWAS studies. 6, 9 In both studies, associated regions were identified by a combination of genomewide and Immunochip genotype data. Although the inclusion of genes identified by the Immunochip potentially introduces more immune-related genes into the initial gene set, such emphasis is supported by known IBD pathophysiology, and therefore, should be represented in pathway and ontology terms identified by the different models as a characteristic of IBD-risk genes. In both studies, some of the IBD-associated regions were identified based on genome-wide genotype data, which is not limited to singlenucleotide polymorphisms relevant to immune-mediated diseases. This ensures representation of genes not related to immunity in the initial gene set, which drives the models to identify additional pathway and ontology features that are not directly related to immunity.
Reviewing the features identified to be characteristic of IBD-risk genes, the ones that had positive calculated coefficients (Fig. 1) , and therefore, are likely to be observed in an IBD gene included immune response (GO:0006955) and inflammatory response (GO:0006954). Positively associated pathways included known IBD-associated pathways such as cell adhesion molecules (KEGG:hsa04514), JAK STAT signaling (KEGG:hsa04630), arachidonic acid metabolism (KEGG:hsa00590), and cytokine-cytokine receptor interaction (KEGG:hsa04060). [30] [31] [32] [33] One less obvious feature identified to be characteristic of IBD genes was the sulfur metabolism pathway (KEGG:hsa00920) supporting the role of host-microbiome interactions in IBD pathogenesis. 34 Features with negative coefficients and therefore less likely to be found in IBD-risk genes included oxidation reduction process (GO:0055114), complement and coagulation cascades (KEGG:hsa04610), calcium ion binding (GO:0005509), transport (GO:0006810), mitochondrion (GO:0005739), and focal adhesion (KEGG:hsa04510). Interestingly, reviewing the features corresponding to expression data, there were significantly more features corresponding to normal samples within the negatively associated features when compared with the positively associated features (11/23 versus 2/39, respectively; Fisher's exact test; P , 0.0005) demonstrating that genes with high expression in normal samples are less likely to be IBD-risk genes. We then went on to review the importance scores calculated for each feature in 3 of the applied models (glmnet, rf, and xgbTree). These scores convey the relative contribution of each feature to the model list, all the articles ever published that concern IBD. Here, we demonstrate the probability for a gene within a given score range to have at least 1 IBD-related publication. Calculated scores were significantly associated with having an IBD publication and high scores (.0.8) demonstrated a significant increase in probability of having an IBD publication across models when compared with lower scores (,0.3).
performance. Despite representing only 20% of the features used by the models (N ¼ 62/309), features corresponding to expression data demonstrated greater contribution to model performance in 2 of the 3 models (20.2%, 76.1%, and 53.1% of the overall sum of scores in the glmnet, rf, and xgbTree models, respectively).
Overall, 347 genes had a high prediction score (.0.8). These genes can be used in studies evaluating genome/exome sequences to narrow down the search space for candidate variants. Of these 347 genes, 163 are known IBD-risk genes, which were used to train the models. Reviewing the remaining 184 genes, at least 1 IBD publication was found for 117, but we could not find any IBD publication for the remaining 67 genes. These genes represent novel candidate IBD-risk genes, which can be targeted in future studies (Table 2) .
Here, we present a supervised machine learning-based method for the classification and prioritization of genes according to their association to IBD based on multilayer characterization of known IBD genes. The genetic architecture of many additional disorders has been studied for a long time using various genetic approaches including GWAS, gene expression analyzes, and sequencing. These disorders include type 2 diabetes mellitus, 35 Parkinson's disease, 36 systemic lupus erythematosus, 37 and coronary artery disease 38 to name a few. The method described in this work represents a complementary approach to the identification of genes and pathways associated with such complex diseases, which may have been missed by the aforementioned conventional methods. Our method successfully differentiated IBD-risk genes from non-IBD genes by using information from expression data and a multitude of gene annotations. The method demonstrated high AUC on both training and test sets and consistently ranked IBD genes in the top percentiles in a randomized score rank test. The clear association between having a high prediction score and having an IBD-related publication establishes, in an independent manner, the validity of our IBD-risk genes prioritization method. We demonstrate how the vast data existing in the public domain may be used to study complex disorders. The method identified novel features that were either associated with IBD or are less likely to characterize an IBD gene. Moreover, the method uncovered gene candidates that have not yet been studied in the context of IBD. We hope that studying this list of IBD-risk genes and the various features identified by our model to be crucial IBD characteristics, will improve the understanding of IBD pathogenesis and progression, and may suggest new drug targets. The 20 top-scoring genes with at least 1 IBD publication are presented together with the 20 top-scoring genes without an IBD publication. The latter represents novel candidate IBD-risk genes. These lists do not include genes that were part of the original list of known IBD-risk genes.
